A key theme at the AD/PD 2025 has been the safety profile of DMTs, focusing on the issue of ARIA, a significant side effect of the Aβ mAb drug class.

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) ...

DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...

Results from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Previously referred to as NTLA-2001, nex-z is an in vivo ‘CRISPR-based’ therapy. Credit: Volha_R/Shutterstock. Intellia Therapeutics has commenced subject dosing in the randomised pivotal Phase III ...

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...